Related Experiment Video
Updated: Oct 15, 2025
A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
Published on: April 28, 2019
A case of acute encephalopathy and non-ST segment elevation myocardial infarction following mRNA-1273 vaccination:
Sabrina Yesmin Barsha1, Miah Md Akiful Haque2, Md Utba Rashid3
1Ibn Sina Medical College Hospital, Kallyanpur, Dhaka, Bangladesh.
Abstract:
A 77-year-old man with a past medical history of type 2 diabetes mellitus, peripheral neuropathy, and chronic obstructive pulmonary disease was admitted to the intensive care unit of Bangladesh Medical College Hospital with acute encephalopathy and non-ST segment elevation myocardial infarction (NSTEMI). The patient was on antidiabetic medicine along with H2 blocker and multivitamins for his existing diseases. The patient's attendant reported that the patient had received his first dose of the Moderna coronavirus disease 2019 (COVID-19) vaccine just 2 days ago. Physical examination revealed that he had a Glasgow Coma Scale of 8/15; a pulse of 106 beats/min; a respiratory rate of 30 breaths/min; oxygen saturation of 80% on room air, which became with 10 L of oxygen and blood pressure of 90/60 mm Hg at the time of admission. During the hospital stay, the patient was treated conservatively with intravenous antibiotics and other necessary medication. Although we have observed the onset of encephalopathy and NSTEMI following COVID vaccination for this patient, we, as healthcare professionals, cannot directly attribute the cause of the complications to the Moderna vaccine without further epidemiological studies with large samples.
Insights
A 77-year-old man developed acute encephalopathy and myocardial infarction shortly after receiving the Moderna COVID-19 vaccine. Further studies are needed to determine if the vaccine caused these serious adverse events.
Area of Science:
- Neurology
- Cardiology
- Vaccinology
Background:
- A 77-year-old male with type 2 diabetes, peripheral neuropathy, and COPD presented with acute encephalopathy and non-ST segment elevation myocardial infarction (NSTEMI).
- The patient had received his first dose of the Moderna coronavirus disease 2019 (COVID-19) vaccine two days prior to admission.
Observation:
- Clinical presentation included a Glasgow Coma Scale of 8/15, tachycardia (106 bpm), tachypnea (30 breaths/min), hypoxia (80% on room air), and hypotension (90/60 mm Hg).
- The patient was managed conservatively with intravenous antibiotics and supportive care.
Findings:
- The patient experienced onset of acute encephalopathy and NSTEMI following COVID-19 vaccination.
- Causality between the Moderna vaccine and the observed complications could not be definitively established without larger epidemiological studies.
Implications:
- This case highlights the importance of monitoring for potential adverse events following COVID-19 vaccination.
- Further research is warranted to investigate the potential association between mRNA vaccines and neurological or cardiac events.
More Related Videos
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022
12:24Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
Related Concept Videos
01:14Myocarditis III: Medical Management
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:21Myocarditis I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:51Vaccinations